Sign in or create an account to add this stock to your watchlist.
About Viveve Medical (NASDAQ:VIVE)
Viveve Medical, Inc. designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable accessories. It markets its products through sales employees and distributors in the United States, the Asia Pacific, Europe, the Middle East, Latin America, and Canada. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VIVE
CUSIPN/A
Phone720-696-8100
Debt
Debt-to-Equity Ratio1.55
Current Ratio6.47
Quick Ratio6.00
Price-To-Earnings
Trailing P/E Ratio-0.87
Forward P/E Ratio-1.19
P/E GrowthN/A
Sales & Book Value
Annual Sales$15.29 million
Price / Sales3.76
Cash FlowN/A
Price / CashN/A
Book Value$0.61 per share
Price / Book3.02
Profitability
EPS (Most Recent Fiscal Year)($2.11)
Net Income$-36,950,000.00
Net Margins-269.24%
Return on Equity-437.98%
Return on Assets-103.63%
Miscellaneous
Employees103
Outstanding Shares31,270,000
Viveve Medical (NASDAQ:VIVE) Frequently Asked Questions
What is Viveve Medical's stock symbol?
Viveve Medical trades on the NASDAQ under the ticker symbol "VIVE."
How were Viveve Medical's earnings last quarter?
Viveve Medical (NASDAQ:VIVE) issued its quarterly earnings data on Thursday, May, 10th. The company reported ($0.49) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.44) by $0.05. The firm had revenue of $3.70 million for the quarter, compared to analysts' expectations of $4.68 million. Viveve Medical had a negative net margin of 269.24% and a negative return on equity of 437.98%. View Viveve Medical's Earnings History.
What price target have analysts set for VIVE?
8 equities research analysts have issued 12 month price objectives for Viveve Medical's shares. Their forecasts range from $6.00 to $11.00. On average, they expect Viveve Medical's stock price to reach $9.3333 in the next twelve months. View Analyst Ratings for Viveve Medical.
What are Wall Street analysts saying about Viveve Medical stock?
Here are some recent quotes from research analysts about Viveve Medical stock:
- 1. Mizuho analysts commented, "We expect the trends in utilization and pricing to continue in 2018. FDA Approval of IDE to Conduct VIVEVE2 Clinical Trial. The FDA approved Viveve’s IDE to conduct a sexual function study in the U.S. The study is expected to start in 2Q18 and will include approximately 250 patients across 25 clinical sites in the U.S. and Canada. The primary endpoint will measure the mean change from baseline in the total FSFI (Female Sexual Function Index) at 12 months. Data from the study is expected in 2H19. Cash Position and Upcoming Catalysts. Viveve’s current cash position stands at approximately $55.7 mil following a recent $35.0 mil equity offering in February." (3/20/2018)
- 2. Maxim Group analysts commented, "4Q17 revenue of $5.1M, up 108% y/y, was inline with the preannouncement." (3/16/2018)
Who are some of Viveve Medical's key competitors?
Some companies that are related to Viveve Medical include Helius Medical Technologies (HSDT), Fonar (FONR), Second Sight Medical Products (EYES), Biolife Solutions (BLFS), Zynex (ZYXI), IRIDEX (IRIX), Edap Tms (EDAP), Semler Scientific (SMLR), BioSig Technologies (BSGM), Stereotaxis (STXS), Soleno Therapeutics (SLNO), Digirad (DRAD), Dynatronics (DYNT), Nexeon MedSystems (NXNN) and Aradigm (ARDM).
Who are Viveve Medical's key executives?
Viveve Medical's management team includes the folowing people:
- Ms. Patricia K. Scheller, CEO & Chairperson (Age 58)
- Mr. James Gregory Atkinson, Chief Bus. Officer & Pres (Age 60)
- Mr. Scott C. Durbin, CFO & Sec. (Age 49)
- Mr. Martin Kerber, VP of Operations
- Mr. Jim B. Robbins, VP of Fin. & Admin. (Age 54)
When did Viveve Medical IPO?
(VIVE) raised $13 million in an IPO on Tuesday, June 14th 2016. The company issued 1,600,000 shares at $8.00 per share. Ladenburg Thalmann and Craig-Hallum Capital Group acted as the underwriters for the IPO and Maxim Group was co-manager.
Has Viveve Medical been receiving favorable news coverage?
Media headlines about VIVE stock have trended somewhat positive recently, Accern reports. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Viveve Medical earned a coverage optimism score of 0.19 on Accern's scale. They also gave news articles about the company an impact score of 45.13 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are Viveve Medical's major shareholders?
Viveve Medical's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include venBio Select Advisor LLC (4.90%), BlackRock Inc. (2.50%), Wexford Capital LP (2.23%), Acuta Capital Partners LLC (2.19%), ING Groep NV (1.38%) and Northern Trust Corp (0.81%). Company insiders that own Viveve Medical stock include James G Atkinson, Patricia Scheller, Scott Durbin and Stonepine Capital Management,. View Institutional Ownership Trends for Viveve Medical.
Which major investors are buying Viveve Medical stock?
VIVE stock was acquired by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Wexford Capital LP, Acuta Capital Partners LLC, ING Groep NV, Northern Trust Corp, BlackRock Inc. and Spark Investment Management LLC. Company insiders that have bought Viveve Medical stock in the last two years include James G Atkinson, Patricia Scheller, Scott Durbin and Stonepine Capital Management,. View Insider Buying and Selling for Viveve Medical.
How do I buy shares of Viveve Medical?
Shares of VIVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Viveve Medical's stock price today?
One share of VIVE stock can currently be purchased for approximately $1.84.
How big of a company is Viveve Medical?
Viveve Medical has a market capitalization of $54.72 million and generates $15.29 million in revenue each year. The company earns $-36,950,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Viveve Medical employs 103 workers across the globe.
How can I contact Viveve Medical?
Viveve Medical's mailing address is 345 INVERNESS DRIVE SOUTH BUILDING B SUITE 250, ENGLEWOOD CO, 80112. The company can be reached via phone at 720-696-8100 or via email at [email protected]
MarketBeat Community Rating for Viveve Medical (VIVE)
MarketBeat's community ratings are surveys of what our community members think about Viveve Medical and other stocks. Vote "Outperform" if you believe VIVE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VIVE will underperform the S&P 500 over the long term. You may vote once every thirty days.
Viveve Medical (NASDAQ:VIVE) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for Viveve Medical in the last 12 months. Their average twelve-month price target is $9.3333, suggesting that the stock has a possible upside of 407.25%. The high price target for VIVE is $11.00 and the low price target for VIVE is $6.00. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.88 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $9.3333 | $9.4286 | $10.00 | $10.40 |
| Price Target Upside: | 407.25% upside | 180.61% upside | 172.48% upside | 116.22% upside |
Viveve Medical (NASDAQ:VIVE) Consensus Price Target History
Viveve Medical (NASDAQ:VIVE) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
Viveve Medical (NASDAQ:VIVE) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Viveve Medical (NASDAQ VIVE) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 35.10%
Institutional Ownership Percentage: 64.83%
Viveve Medical (NASDAQ VIVE) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/23/2017 | Scott Durbin | CFO | Buy | 5,000 | $5.25 | $26,250.00 | 11,568 |  |
| 3/17/2017 | James G Atkinson | Director | Buy | 375,000 | $4.00 | $1,500,000.00 | 11,525 | |
| 3/17/2017 | Patricia Scheller | CEO | Buy | 12,500 | $4.00 | $50,000.00 | 45,164 | |
| 6/17/2016 | James G. Atkinson | Insider | Buy | 100,000 | $5.00 | $500,000.00 | | |
| 6/17/2016 | Patricia Scheller | CEO | Buy | 6,000 | $5.00 | $30,000.00 | | |
| 6/17/2016 | Scott Durbin | CFO | Buy | 1,500 | $5.00 | $7,500.00 | | |
| 6/17/2016 | Stonepine Capital Management, | Major Shareholder | Buy | 300,000 | $5.00 | $1,500,000.00 | | |
| 9/23/2014 | 5Am Partners Ii, Llc | Major Shareholder | Buy | 5,215,664 | $0.53 | $2,764,301.92 | | |
| 9/23/2014 | Daniel Janney | Director | Buy | 1,895,788 | $0.53 | $1,004,767.64 | | |
(Data available from 1/1/2013 forward)
Viveve Medical (NASDAQ VIVE) News Headlines
| Source: |
|
Viveve Medical (NASDAQ:VIVE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Viveve Medical (NASDAQ:VIVE) Income Statement, Balance Sheet and Cash Flow Statement
Viveve Medical (NASDAQ VIVE) Stock Chart for Thursday, May, 24, 2018
Loading chart…
